Olverembatinib in chronic myeloid leukemia: is less actually better?

Authors

María Agustina Perusini (ORCID: https://orcid.org/0000-0003-1893-6096)
Dennis Dong Hwan Kim (ORCID: https://orcid.org/0000-0003-2640-4911)

Institutions

Princess Margaret Cancer Centre (CA)

Publication Details

Journal: Haematologica
Published: 2025-06-19
DOI: https://doi.org/10.3324/haematol.2025.288065
Primary Topic: Chronic Myeloid Leukemia Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Olverembatinib in chronic myeloid leukemia: is less actually better?

María Agustina Perusini, Dennis Dong Hwan Kim

Jun 19, 2025

Haematologica

Chronic Myeloid Leukemia Treatments

article

Olverembatinib in chronic myeloid leukemia: is less actually better?

María Agustina Perusini, Dennis Dong Hwan Kim

June 19, 2025article en

Abstract

No abstract available for this paper.

HaematologicaVol. 110(12)

Princess Margaret Cancer Centre (CA)

Openalex Percentile: Top 82%

Chronic Myeloid Leukemia Treatments

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Olverembatinib in chronic myeloid leukemia: is less actually better? — María Agustina Perusini, Dennis Dong Hwan Kim · Haematologica (2025) | TGRS Research Map | TGRS